Nov 3 (Reuters) - French biotechnology firm Biomérieux BIOX.PA reported on Tuesday a better-than-expected organic sales growth in the third quarter, helped by a 13% increase in sales from GO 28 growth drivers.
Total sales for the period came in at €1,042 million ($1.17 billion), up 8% year on year, above the company's compiled median consensus for sales of €1,007 billion and organic growth of 5.9%.
($1 = 0.8937 euros)
Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
